These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 29552925

  • 1. [The efficacy and safety of edoxaban in non-valvular atrial fibrillation].
    Szegedi A, Csanádi Z.
    Orv Hetil; 2018 Mar; 159(12):466-469. PubMed ID: 29552925
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E.
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [Abstract] [Full Text] [Related]

  • 3. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY, ENSURE-AF investigators.
    Lancet; 2016 Oct 22; 388(10055):1995-2003. PubMed ID: 27590218
    [Abstract] [Full Text] [Related]

  • 4. Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
    Dzeshka MS, Lip GY.
    Expert Opin Pharmacother; 2015 Oct 22; 16(17):2661-78. PubMed ID: 26559069
    [Abstract] [Full Text] [Related]

  • 5. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
    Geller BJ, Giugliano RP, Braunwald E, Murphy SA, Hanyok JJ, Jin J, Mercuri M, Antman EM, Ruff CT.
    Am Heart J; 2015 Oct 22; 170(4):669-74. PubMed ID: 26386790
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials.
    Chen J, Zhuang X, Long M, Su C, Wang L.
    J Stroke Cerebrovasc Dis; 2015 Dec 22; 24(12):2710-9. PubMed ID: 26324517
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
    Magnani G, Giugliano RP, Ruff CT, Murphy SA, Nordio F, Metra M, Moccetti T, Mitrovic V, Shi M, Mercuri M, Antman EM, Braunwald E.
    Eur J Heart Fail; 2016 Sep 22; 18(9):1153-61. PubMed ID: 27349698
    [Abstract] [Full Text] [Related]

  • 8. Edoxaban: a review in nonvalvular atrial fibrillation.
    McCormack PL.
    Am J Cardiovasc Drugs; 2015 Oct 22; 15(5):351-61. PubMed ID: 26369340
    [Abstract] [Full Text] [Related]

  • 9. [Stroke prevention in the elderly: effectiveness and safety of edoxaban in elderly patients according to the results of the ENGAGE AF study].
    Márk L.
    Orv Hetil; 2018 May 22; 159(20):798-802. PubMed ID: 29754512
    [Abstract] [Full Text] [Related]

  • 10. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
    Kubli KA, Snead JA, Cheng-Lai A.
    Cardiol Rev; 2016 May 22; 24(4):205-10. PubMed ID: 26991962
    [Abstract] [Full Text] [Related]

  • 11. [The ENGAGE AF-TIMI 48 study].
    Rubboli A, Colonna P.
    G Ital Cardiol (Rome); 2015 Sep 22; 16(9):457-61. PubMed ID: 26418383
    [No Abstract] [Full Text] [Related]

  • 12. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY, Merino J, Ezekowitz M, Ellenbogen K, Zamoryakhin D, Lanz H, Jin J, Al-Saadi N, Mercuri M, Goette A.
    Am Heart J; 2015 May 22; 169(5):597-604.e5. PubMed ID: 25965706
    [Abstract] [Full Text] [Related]

  • 13. Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban.
    Masjuan J, DeFelipe A.
    Int J Neurosci; 2017 Aug 22; 127(8):716-725. PubMed ID: 27586690
    [Abstract] [Full Text] [Related]

  • 14. The safety of edoxaban for treating atrial fibrillation.
    Hammwöhner M, Goette A.
    Expert Opin Drug Saf; 2017 Nov 22; 16(11):1295-1303. PubMed ID: 28862063
    [Abstract] [Full Text] [Related]

  • 15. First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial.
    Steffel J, Ruff CT, Hamershock RA, Murphy SA, Senior R, Roy D, Lanz HJ, Mercuri MF, Antman EM, Giugliano RP.
    Int J Cardiol; 2017 Oct 01; 244():192-195. PubMed ID: 28625512
    [Abstract] [Full Text] [Related]

  • 16. Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
    Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, Aylward P, White H, Zamorano JL, Antman EM, Ruff CT.
    J Am Coll Cardiol; 2016 Sep 13; 68(11):1169-1178. PubMed ID: 27609678
    [Abstract] [Full Text] [Related]

  • 17. Edoxaban for the prevention of stroke in patients with atrial fibrillation.
    Cervantes CE, Merino JL, Barrios V.
    Expert Rev Cardiovasc Ther; 2019 Apr 13; 17(4):319-330. PubMed ID: 30897988
    [Abstract] [Full Text] [Related]

  • 18. Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.
    Corbalán R, Nicolau JC, López-Sendon J, Garcia-Castillo A, Botero R, Sotomora G, Horna M, Ruff CT, Hamershock RA, Grip LT, Antman EM, Braunwald E, Giugliano RP.
    J Am Coll Cardiol; 2018 Sep 25; 72(13):1466-1475. PubMed ID: 30236308
    [Abstract] [Full Text] [Related]

  • 19. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
    Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT, Greenberger NJ, Yin OQP, Choi Y, Lanz HJ, Mercuri MF, Braunwald E, Giugliano RP.
    J Am Coll Cardiol; 2019 Jul 16; 74(2):179-189. PubMed ID: 31296289
    [Abstract] [Full Text] [Related]

  • 20. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
    Giugliano RP, Ruff CT, Wiviott SD, Nordio F, Murphy SA, Kappelhof JA, Shi M, Mercuri MF, Antman EM, Braunwald E.
    Am J Med; 2016 Aug 16; 129(8):850-857.e2. PubMed ID: 26994510
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.